Anti-Mouse CXCL9 (Clone MIG-2F5-5) – Purified in vivo GOLD™ Functional Grade

Anti-Mouse CXCL9 (Clone MIG-2F5-5) – Purified in vivo GOLD™ Functional Grade

Product No.: C793

[product_table name="All Top" skus="D353"]

- -
- -
Clone
MIG-2F5-5
Target
CXCR3
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
MIG-1, MIG
Isotype
IgG
Applications
FC
,
IF
,
in vivo
,
N

- -
- -
Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Armenian Hamster
Immunogen
Mouse plasmacytoid dendritic cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC
Additional Applications Reported In Literature ?
N IF
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
MIG-2F5-5 activity is directed against murine CXCL9 (monokine induced by gamma interferon, MIG).
Antigen Distribution
CXCL9 is mainly secreted by macrophages, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ and is also expressed in intratumoral dendritic cells.
Background
CXCL9 is a chemokine, which are small 8-15 kDa proteins that function in immune responses1. CXCL9, -10, -11 and their receptor CXCR3 regulate immune cell migration, differentiation, and activation, leading to tumor suppression in the paracrine axis. However, in the autocrine axis, they may be involved in tumor growth and metastasis. The CXCL9, -10, -11/CXCR3 axis also regulates differentiation of naïve T cells to T helper 1 (Th1) cells. CXCL9, -10, and -11 are usually expressed at low levels but are upregulated by cytokine stimulation. CXCL9 is dependent on IFNγ for expression2. CXCL9 is also capable of direct antimicrobial activity against pathogen infection3. CXCL9 is secreted by macrophages4, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ1 and is also expressed in intratumoral dendritic cells5. CXCL9 is also detectable in CD103+ conventional dendritic cells (cDCs) isolated from transgenic murine MMTV-PyMT tumors following in vivo administration of brefeldin A5. Additionally, CXCL9 is detectable in myeloid cells following ex vivo stimulation with IFN-γ. Furthermore, CXCL9 expression is enhanced in CD8α+ cDC1s when anti-TIM-3 is added. Neutralizing antibodies against Galectin-9 lead to an increase in CXCL9 expression comparable to that induced by anti-TIM-3 antibody. Additionally, endothelial cell expression of CXCL9 is strongly increased in liver sinusoidal endothelial cells isolated from nonalcoholic steatohepatitis mouse livers6. MIG-2F5-5 was generated by immunizing male Armenian hamsters with recombinant murine CXCL9, and specificity was confirmed by ELISA7.

Antigen Details

NCBI Gene Bank ID
Research Area
Immunology

References & Citations

1. Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018.
2. Cole KE, Strick CA, Paradis TJ, et al. J Exp Med. 187: 2009–2021. 1998.
3. Reid-Yu SA, Tuinema BR, Small CN, et al. PLoS Pathog. 11(2):e1004648. 2015.
4. Marcovecchio PM, Thomas G, Salek-Ardakani S. J Immunother Cancer. 9(2):e002045. 2021.
5. de Mingo Pulido Á, Gardner A, Hiebler S, et al. Cancer Cell. 33(1):60-74.e6. 2018.
6. Xiong X, Kuang H, Ansari S, et al. Mol Cell. 75(3):644-660.e5. 2019.
7. Krug A, Uppaluri R, Facchetti F, et al. J Immunol. 169(11):6079-6083. 2002.
8. Asai A, Tsuda Y, Kobayashi M, et al. Infect Immun. 78(10):4311-4319. 2010.
Flow Cytometry
IF
in vivo Protocol
N

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.